NASDAQ$TECX
Tectonic Therapeutic Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Tectonic Therapeutic Inc reported a net loss of 19984000 for Q2 2025.
Tectonic Therapeutic Inc, a clinical-stage biotechnology company, reported operating expenses of 22332000 for the three months ended June 30, 2025, driven by research and development costs of 17185000 and general and administrative expenses of 5147000. The company recorded interest income of 3389000, resulting in a net loss of 19984000 or 1.07 per share. Cash and cash equivalents stood at 287381000 with total assets of 295313000 as of the quarter end.
- Net loss of 19984000 for the quarter, with EPS of -1.07 on 18680042 weighted average shares.
- Research and development expenses increased to 17185000, reflecting ongoing clinical trials for TX45 and TX2100.
- Strong liquidity position with 287381000 in cash and cash equivalents supporting operations.
- Total operating expenses reached 22332000, leading to operating loss of 22332000 offset partially by other income.
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Forward guidance
Company plans to report topline results from APEX Phase 2 trial in 2026 and initiate additional Phase 2 trial in PH-ILD.
Tailwinds
- Favorable Phase 1b data for TX45 in PH-HFpEF patients.
- Strong cash position of over 287 million to fund operations.
Headwinds
- Continued net losses expected as development advances.
- No product revenue generated to date.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-1.2%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +1.6% | — | — | |
| Q2 2024 | — | — | — | |
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro